We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current STRO market cap is 216.38M. The company's latest EPS is USD -1.7520 and P/E is -1.98.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 25.15M | 8.63M | 12.67M | 10.41M | 16.92M |
| Operating Income | -21.21M | -49.22M | -42.24M | -46.18M | -44.01M |
| Net Income | -19.49M | -34.59M | -50.05M | -38.52M | -49.28M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 42.74M | 42.72M | 61.88M | 67.77M | 153.73M |
| Operating Income | -55.47M | -71.06M | -98.52M | -128.94M | -89.28M |
| Net Income | -55.74M | -32.13M | -105.54M | -119.2M | -106.79M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 400.7M | 406.94M | 358.02M | 464.9M | 431.73M |
| Total Liabilities | 170.97M | 189.9M | 172.6M | 310.18M | 319.39M |
| Total Equity | 229.73M | 217.05M | 185.41M | 154.72M | 112.35M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 156.37M | 394.11M | 341.41M | 406.94M | 470.74M |
| Total Liabilities | 58.58M | 62.06M | 88.84M | 189.9M | 321.09M |
| Total Equity | 97.79M | 332.05M | 252.56M | 217.05M | 149.65M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 27.41M | 3.55M | -60.99M | -92.19M | -125.69M |
| Investing | 2.86M | -35.02M | 67.45M | 133.61M | 19.59M |
| Financing | 36.09M | 48.31M | 8.76M | 146.42M | 140.68M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -65.02M | -67.8M | -81.68M | 3.55M | -111.62M |
| Investing | -51.13M | 604k | -97.32M | -35.02M | -3.92M |
| Financing | -4.18M | 269.25M | 3.26M | 48.31M | 137.55M |
| Market Cap | 216.38M |
| Price to Earnings Ratio | -1.98 |
| Price to Sales Ratio | 1.38 |
| Price to Cash Ratio | 3.05 |
| Price to Book Ratio | 1.41 |
| Dividend Yield | - |
| Shares Outstanding | 60.95M |
| Average Volume (1 week) | 648.67k |
| Average Volume (1 Month) | 1.33M |
| 52 Week Change | -24.63% |
| 52 Week High | 6.13 |
| 52 Week Low | 2.005 |
| Spread (Intraday) | 0.16 (4.41%) |
| Company Name | Sutro Biopharma Inc |
| Address |
310 utah ave., suite 150 south san francisco, california 94080 |
| Website | https://www.sutrobio.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
